INFLUENCE of STUDY DESIGN on TREATMENT RESPONSE in ANXIETY DISORDER CLINICAL TRIALS

Depression and Anxiety

Volumn 32, Issue 12, 2015, Pages 944-957

  Rutherford, Bret R ^a   Bailey, Veronika S ^b   Schneier, Franklin R ^a   Pott, Emily ^b   Brown, Patrick J ^a   Roose, Steven P ^a  

^a New York State Psychiatric Institute ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

antidepressants; anxiety anxiety disorder; clinical trials; pharmacotherapy; treatment

Indexed keywords

ATENOLOL; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HYDROXYZINE; IMIPRAMINE; MAPROTILINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; VORTIOXETINE; ZIMELDINE;

ANXIETY DISORDER; ARTICLE; DISEASE SEVERITY; DRUG RESPONSE; FOLLOW UP; GENERAL CONDITION IMPROVEMENT; GENERALIZED ANXIETY DISORDER; HUMAN; PANIC; PATIENT ATTITUDE; PRIORITY JOURNAL; SOCIAL PHOBIA; STATISTICAL MODEL; STUDY DESIGN; ADULT; ANXIETY DISORDERS; CLINICAL TRIAL (TOPIC); FEMALE; MALE; METHODOLOGY; PANIC DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA;

ADULT; ANXIETY DISORDERS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; PANIC DISORDER; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SEROTONIN UPTAKE INHIBITORS;

EID: 84949556541     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22433     Document Type: Article

References (99)

1. Walsh BT, Seidman SN, Sysko R, Gould M,. Placebo response in studies of major depression: variable, substantial, and growing. J Am Med Assoc 2002; 287: 1840-1847.
2. Rutherford BR, Pott E, Tandler JM, et al., Placebo response in antipsychotic clinical trials: a meta-analysis. J Am Med Assoc Psychiatry 2014; 71: 1409-1421.
3. Fava M, Evins AE, Dorer DJ, Schoenfeld DA,. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003; 72: 115-127.
4. Andrews G., Placebo response in depression: bane of research, boon to therapy. Br J Psychiatry 2001; 178: 192-194.
5. Rutherford BR, Roose SP,. A model of placebo effects in antidepressant clinical trials. Am J Psychiatry 2013; 170: 723-733.
6. Mayberg HS, Silva JA, Brannan SK, et al., The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002; 159: 728-737.
7. Schweizer E, Rickels K,. Placebo response in generalized anxiety: its effect on the outcome of clinical trials. J Clin Psychiatry 1997; 58 (Suppl 11): 30-38.
8. Stein DJ, Baldwin DS, Dolberg OT, Despiegel N, Bandelow B,. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of Escitalopram. J Clin Psychiatry 2006; 67: 1741-1746.
9. Piercy MA, Sramek JJ, Kurtz NM, Cutler NR,. Placebo response in anxiety disorders. Ann Pharmacother 1996; 30: 1013-1019.
10. Khan A, Kolts RL, Rapaport MH, et al., Magnitude of placebo response and drug-placebo differences across psychiatric disorders. Psychol Med 2005; 35: 743-749.
11. Feltner D, Hill C, Lenderking W, Williams V, Morlock R,. Development of a patient-reported assessment to identify placebo responders in a generalized anxiety disorder trial. J Psychiatr Res 2009; 43: 1224-1230.
12. Uhlenhuth EH, Matuzas W, Warner TD, Thompson PM,. Growing placebo response rate: the problem in recent therapeutic trials? Psychopharmacol Bull 1997; 33: 31-39.
13. Cohen D, Consoli A, Bodeau N, et al., Predictors of placebo response in randomized controlled trials of psychotropic drugs for children and adolescents with internalizing disorders. J Child Adolesc Psychopharmacol 2010; 20: 39-47.
14. Rutherford BR, Sneed JR, Roose SP,. Does study design affect outcome? The effects of placebo control and treatment duration in antidepressant trials. Psychother Psychosom 2009; 78: 172-181.
15. Rutherford BR, Sneed JR, Tandler J, Peterson BS, Roose SP,. Deconstructing pediatric depression trials: an analysis of the effects of expectancy and therapeutic contact. J Am Acad Child Adolesc Psychiatry 2011; 50: 782-795.
16. Bryk AS, Raudenbush SW,. Hierarchical Linear Models. Newbury Park, CA: Sage Publications; 1992.
17. Hox J,. Multilevel Analysis: Techniques and Applications. Mahwah, NJ: Lawrence Erlbaum Publishers; 2002.
18. Haddock CK, Rindskopf D, Shadish WR., Using odds ratios as effect sizes for meta-analysis of dichotomous data: a primer on methods and issues. Psychol Methods 1998; 3: 339-353.
19. Rutherford BR, Sneed JR, Tandler J, Peterson BS, Roose SP,. Deconstructing pediatric depression trials: an analysis of the effects of expectancy and therapeutic contact. J Am Acad Child Adolesc Psychiatry 2011; 50: 782-795.
20. Rutherford BR, Tandler J, Brown P, Sneed JR, Roose SP,. Clinic visits in late life depression trials: effects on signal detection and therapeutic outcome. Am J Geriatr Psychiatry 2014; 22: 1452-1461.
21. Higgins JPT, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
22. Takkouche B, Cadarso Surez C, Spiegelman D,. Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am J Epidemiol 1999; 150: 206-215.
23. Allgulander C., Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand 1999; 100: 193-198.
24. Allgulander C, Dahl AA, Austin C, et al., Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 2004; 161: 1642-1649.
25. Allgulander C, Hartford J, Russell J, et al., Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials. Curr Med Res Opin 2007; 23: 1245-1252.
26. Allgulander C, Mangano R, Zhang J, et al., Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 2004; 19: 387-396.
27. Asakura S, Tajima O, Koyama T,. Flovoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2007; 10: 263-274.
28. Asnis GM, Hameedi FA, Goddard AW, et al., Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res 2001; 103: 1-14.
29. Baldwin D, Bobes J, Stein DJ, Scharwachter I, Faure M,. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine study group. Br J Psychiatry 1999; 175: 120-126.
30. Baldwin DS, Huusom AK, Maehlum E,. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br J Psychiatry 2006; 189: 264-272.
31. Ball SG, Kuhn A, Wall D, Shekhar A, Goddard AW,. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry 2005; 66: 94-99.
32. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP,. Double-blind, fixed dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998; 155: 36-42.
33. Bandelow B, Behnke K, Lenoir S, et al., Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J Clin Psychiatry 2004; 65: 405-413.
34. Bielski RJ, Bose A, Chang CC,. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005; 17: 65-69.
35. Bidzan L, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV,. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. Eur Neuropsychopharmacol 2012; 22: 847-857.
36. Den Boer JA, Westenberg HG,. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988; 3: 59-74.
37. Bose A, Korotzer A, Gommoll C, Li D,. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Depress Anxiety 2008; 25: 854-861.
38. Bradwejn J, Ahokas A, Stein DJ, et al., Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 2005; 187: 352-359.
39. Brawman-Mintzer O, Knapp RG, Rynn M, Carter RE, Rickels K,. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006; 67: 874-881.
40. Caillard V, Rouillon F, Viel JF, Markabi S,. Comparative effects of low and high doses of clomipramine and placebo in panic disorder: a double-blind controlled study. French University Antidepressant Group. Acta Psychiatr Scand 1999; 99: 51-58.
41. Davidson JR, Bose A, Korotzer A, Zheng H,. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 2004; 19: 234-240.
42. Davidson J, Yaryura-Tobias J, DuPont R, et al., Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004; 24: 118-125.
43. Evans L, Kenardy J, Schneider P, Hoey H,. Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks. A double-blind comparison of zimeldine, imipramine and placebo. Acta Psychiatr Scand 1986; 73: 49-53.
44. Gelenberg AJ, Lydiard RB, Rudolph RL, et al., Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. J Am Med Assoc 2000; 283: 3082-3088.
45. Gommoll C, Durgam S, Mathews M, et al., A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder. Depress Anxiety 2015; 32: 451-459.
46. Kasper S, Stein DJ, Loft H, Nil R,. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 2005; 186: 222-226.
47. Kim TS, Pae CU, Yoon SJ, et al., Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder. Psychiatry Clin Neurosci 2006; 60: 347-351.
48. Kobak KA, Gerist JH, Jefferson JW, Katzelnick DJ,. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 2002; 22: 257-262.
49. Lader M, Scotto JC,. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology (Berl) 1998; 139: 402-406.
50. Lader M, Stender K, Burger V, Nil R,. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004; 19: 241-248.
51. Lecrubier Y, Bakker A, Dunbar G, Judge R,. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997; 95: 145-152.
52. Leinonen E, Lepola U, Koponen H, et al., Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. J Psychiatry Neurosci 2000; 25: 24-32.
53. Lenox-Smith AJ, Reynolds A,. A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. Br J Gen Pract 2003; 53: 772-777.
54. Lepola U, Bergtholdt B, St Lambert J, Davy KL, Ruggiero L,. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry 2004; 65: 222-229.
55. Liebowitz MR, DeMartinis NA, Weihs K, et al., Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry 2003; 64: 785-792.
56. Liebowitz MR, Gelenberg AJ, Munhack D,. Venlafaxine extended release vs. placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005; 62: 190-198.
57. Liebowitz MR, Mangano RM, Bradwejn J, Asnis G, SAD study group. A randomized controlled trial of venlafaxine extended release in generalized anxiety disorder. J Clin Psychiatry 2005; 66: 238-247.
58. Liebowitz MR, Schneier F, Campeas R, et al., Phenelzine vs. atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 1992; 49: 290-300.
59. Londborg PD, Wolkow R, Smith WT, et al., Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 1998; 173: 54-60.
60. Lydiard RB, Morton WA, Emmanuel NP, et al., Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull 1993; 29: 183-188.
61. Mavissakalian MR, Perel JM,. Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships. Am J Psychiatry 1995; 152: 673-682.
62. Michelson D, Allgulander C, Dantendorfer K, et al., Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. Br J Psychiatry 2001; 179: 514-518.
63. Michelson D, Lydiard RB, Pollack MH, et al., Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry 1998; 155: 1570-1577.
64. Modigh K, Westburg P, Eriksson E,. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol 1992; 12: 251-261.
65. Nair NP, Bakish D, Saxena B, et al., Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety 1996; 2: 192-198.
66. Nimatoudis I, Zissis NP, Kogeorgos J, et al., Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study. Int Clin Psychopharmacol 2004; 19: 331-336.
67. Oehrberg S, Christiansen PE, Behnke K, et al., Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995; 167: 374-379.
68. Pohl R, Balon R, Yeragani VK, Gershon S,. Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone. Psychopathology 1989; 22 Suppl 1: 60-67.
69. Pollack MH, Lepola U, Koponen H, et al., A double-blind study of the efficacy of velafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 2007; 24: 1-14.
70. Pollack M, Mangano R, Entusuah R, et al., A randomized controlled trial of velafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl) 2007; 194: 233-242.
71. Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wokow R,. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry 1998; 55: 1010-1016.
72. Pollack MH, Zaninelli R, Goddard A, et al., Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62: 350-357.
73. Ribeiro L, Busnello JV, Kauer-Sant'Anna M, et al., Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res 2001; 34: 1303-1307.
74. Rickels K, Mangano R, Khan A,. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol 2004; 24: 488-496.
75. Rickels K, Pollack MH, Sheehan DV, Haskins JT,. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000; 157: 968-974.
76. Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D,. Paroxetine treatment of generalized anxiety disorder: a double-blind placebo-controlled study. Am J Psychiatry 2003; 160: 749-756.
77. Rothschild AJ, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV,. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol 2012; 22: 858-866.
78. Rynn M, Russell J, Erikson J, et al., Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 2008; 25: 182-189
79. Sheehan DV, Raj AB, Harnett-Sheehan K, Soto S, Knapp E,. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 1993; 88: 1-11.
80. Stahl SM, Gergel I, Li D,. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2003; 64: 1322-1327.
81. Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B,. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 1999; 156: 756-760.
82. Stein MB, Liebowitz MR, Lydiard RB, et al., Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. J Am Med Assoc 1998; 280: 708-713.
83. Van Ameringen MA, Lane RM, Walker JR, et al., Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001; 158: 275-281.
84. Van Ameringen M, Mancini C, Oakman J, et al., Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial. J Clin Psychiatry 2007; 68: 288-295.
85. Van Vliet IM, Westenberg HG, Slaap BR, den Boer JA, Ho Pian KL,. Anxiogenic effects of pentagastrin in patients with social phobia and healthy controls. Biol Psychiatry 1997; 42: 76-78.
86. Wade AG, Lepola U, Koponen HJ, Pederson V, Pederson T,. The effect of citalopram in panic disorder. Br J Psychiatry 1997; 170: 549-553.
87. Westenberg HG, Stein DJ, Yang H, Li D, Barbato LM,. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004; 24: 49-55.
88. Wu W, Wang G, Ball S, Desaiah D, Ang Q,. Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China. Chin Med J 2011; 124: 3260-3268.
89. Sysko R, Walsh BT,. A systematic review of placebo response in studies of bipolar mania. J Clin Psychiatry 2007; 68: 1213-1217.
90. Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA,. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 2009; 166: 42-49.
91. Agid O, Siu CO, Potkin SG, et al., Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010. Am J Psychiatry 2013; 170: 1335-1344.
92. Leucht S, Heres S, Davis JM,. Increasing placebo response in antipsychotic drug trials: let's stop the vicious circle. Am J Psychiatry 2013; 170: 1232-1234.
93. Dager SR, Khan A, Cowley D, et al., Characteristics of placebo response during long-term treatment of panic disorder. Psychopharmacol Bull 1990; 26: 273-278.
94. Albus M, Lecrubier Y, Maier W, et al., Drug treatment of panic disorder: early response to treatment as a predictor of final outcome. Acta Psychiatr Scand 1990; 82: 359-365.
95. Trivedi M, Rush J,. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? Neuropsychopharmacology 1995; 11: 33-43.
96. Marcus SM, Gorman JM, Tu X,. Rater bias in a blinded randomized placebo-controlled psychiatry trial. Stat Med 2006; 25: 2762-2770.
97. Kobak KA, Kane JM, Thase ME, Nierenberg AA,. Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol 2007; 27: 1-5.
98. Brody B, Leon AC, Kocsis JH,. Antidepressant clinical trials and subject recruitment: just who are symptomatic volunteers? Am J Psychiatry 2011; 168: 1245-1247.
99. Posternak MA, Zimmerman M,. Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials. Br J Psychiatry 2007; 190: 287-292.